Entera Bio Ltd.

ENTX Nasdaq SEC CIK 1638097
Follow Entera Bio Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
EPS, diluted $0.11 +57.1% vs same quarter last year
Operating cash flow −$7.4M −195.7% vs same quarter last year
Operating income −$7.3M −123.1% vs same quarter last year
Revenue by quarter
$82K
$42K
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
$0$200K$400K$600KFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenue
FY25$42K
FY24$181K
FY23$0
FY22$134K
FY21$571K
FY20$365K
FY19-
MarginsShare of revenue
  • Gross margin
  • Operating margin
−30000%−20000%−10000%0%10000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating margin
FY250%−27450%
FY245%−5295.6%
FY23--
FY2224.6%−9714.2%
FY2134.7%−2139.6%
FY2017.8%−3059.7%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$7.5M
FY24−$6.8M
FY23−$7.3M
FY22−$12.5M
FY21−$9.1M
FY20−$10.6M
FY19-